Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.17 - $62.40
Previous CloseN/A
Volume180.68K
Average Volume (3M)2.43M
Market Cap
$6.83B
Enterprise Value$4.93B
Total Cash (Recent Filing)$2.10B
Total Debt (Recent Filing)$134.34M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 05, 2025EPS Estimate
-1.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding186,933,200
10 Day Avg. Volume1,455,545
30 Day Avg. Volume2,429,411
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue18.86
Enterprise Value/Gross Profit41.80
Enterprise Value/Ebitda-6.32
Forecast
1Y Price Target
$66.86Price Target Upside91.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical TrialsUpcoming catalysts include the initiation of two pivotal Phase 3 trials for daraxonrasib in pancreatic ductal adenocarcinoma and a Phase 3 trial with Keytruda in NSCLC.
Financial PositionRevolution Medicines is considered one of the best-financed development-stage companies in the precision oncology domain, ending 2Q25 with approximately $2.1 billion in cash and cash equivalents.
Bears Say
Financial PerformanceRevolution recorded a net loss of $1.31 per share, which is wider than the previously estimated net loss of $1.15 per share, primarily due to higher-than-anticipated operating expenses.
RisksRisks include clinical setbacks, inability to secure timely regulatory approval, and possible long-term dilution risk.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $29.17 and its highest was $62.40 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $6.83B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Nov 05, 2025 which is in 87 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Aug 06, 2025. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.138 by -$0.172.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.4.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 186,933,200 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.138. Following the earnings report the stock price went down -4.69%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
Revolution Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.86 (91.03% Upside)
$66.86 (91.03% Upside)
Blogger Sentiment
Neutral
RVMD Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 346.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.31%
12-Months-Change
Fundamentals
Return on Equity
-46.61%
Trailing 12-Months
Asset Growth
34.35%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. (RVMD) is a biotechnology company that operates in the pharmaceutical sector, focusing on the discovery and development of novel targeted therapies for cancer. The company is particularly known for its precision oncology approach, targeting specific genetic mutations and pathways that drive cancer growth and progression. Revolution Medicines' core products are centered around inhibiting critical signaling pathways, such as the RAS and mTOR pathways, which are implicated in various types of cancers.
RVMD Company Deck
RVMD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Revolution Medicines' clinical pipeline and financial strategy, with Breakthrough Therapy designations and robust financial backing. However, increased expenses and net loss, along with uncertain commercialization timelines, present challenges.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$66.86
▲(91.03% Upside)
Technical Analysis
Teleflex
―
The Ensign Group
―
Blueprint Medicines
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
6.42% Insiders
26.90% Mutual Funds
1.32% Other Institutional Investors
52.92% Public Companies and
Individual Investors